BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390-399. [PMID: 26324537 DOI: 10.1093/eurheartj/ehv443] [Cited by in Crossref: 56] [Cited by in F6Publishing: 66] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL 3rd. GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep 2018;8:14529. [PMID: 30266987 DOI: 10.1038/s41598-018-32797-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 [DOI: 10.1101/473728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Kong Q, Ma X, Zhao X, Chen F, Hou C. Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2020;50:942-56. [PMID: 32221808 DOI: 10.1007/s11239-020-02085-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bueno H, Pocock S, Danchin N, Annemans L, Gregson J, Medina J, Van de Werf F. International patterns of dual antiplatelet therapy duration after acute coronary syndromes. Heart 2017;103:132-8. [PMID: 27504002 DOI: 10.1136/heartjnl-2016-309509] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
5 Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstråle W, Held C, Steg PG; THEMIS Steering Committee. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol 2019;42:498-505. [PMID: 30788847 DOI: 10.1002/clc.23164] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
6 Ariotti S, Gargiulo G, Valgimigli M. Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. Curr Cardiol Rep. 2017;19:2. [PMID: 28097533 DOI: 10.1007/s11886-017-0810-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fanaroff AC, Hasselblad V, Roe MT, Bhatt DL, James SK, Steg PG, Gibson CM, Ohman EM. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. Int J Cardiol 2017;241:87-96. [PMID: 28320608 DOI: 10.1016/j.ijcard.2017.03.046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
8 Spiliopoulos S, Pastromas G. Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. World J Cardiol 2015;7:912-21. [PMID: 26730297 DOI: 10.4330/wjc.v7.i12.912] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
9 Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G; REACH Registry Investigators. Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. Clin Cardiol 2016;39:670-7. [PMID: 27588731 DOI: 10.1002/clc.22583] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 5.6] [Reference Citation Analysis]
10 Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 2017;38:804-10. [PMID: 28363222 DOI: 10.1093/eurheartj/ehw525] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
11 Keach JW, Yeh RW, Maddox TM. Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease. Curr Atheroscler Rep 2016;18. [DOI: 10.1007/s11883-015-0553-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
12 Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier P, Iglesias JF. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart 2017;4:e000651. [PMID: 29081979 DOI: 10.1136/openhrt-2017-000651] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
13 Costa F, Valgimigli M. The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. Cardiovasc Diagn Ther 2018;8:630-46. [PMID: 30498687 DOI: 10.21037/cdt.2018.10.01] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
14 De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Collet JP, Halvorsen S, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Ricci F, Sibbing D, Siegbahn A, Storey RF, Ten Berg J, Verheugt FW, Weitz JI. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2016;115:685-711. [PMID: 26952877 DOI: 10.1160/TH15-09-0703] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
15 Chen C, Kan Y, Shi Z, Guo D, Fu W, Li Y, Lv Q, Li X, Si Y. Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis. Front Pharmacol 2020;11:608247. [PMID: 33732144 DOI: 10.3389/fphar.2020.608247] [Reference Citation Analysis]
16 Su J, Li J, Yu Q, Xu X, Wang J, Yang J, Li X, Chen X. Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. J Clin Lab Anal 2019;33:e22867. [PMID: 30891852 DOI: 10.1002/jcla.22867] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
17 Wang HY, Gao RL, Xu B, Yang YJ, Yin D, Wang Y, Dou KF. Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI. Platelets 2021;32:533-41. [PMID: 32498587 DOI: 10.1080/09537104.2020.1774052] [Reference Citation Analysis]
18 Burlacu A, Covic A. Longer or shorter dual antiplatelet therapy in dialysis patients receiving a coronary drug-eluting stent? A rope game still ongoing. Clin Kidney J 2020;13:749-52. [PMID: 33125001 DOI: 10.1093/ckj/sfaa040] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zheng B, Huo Y, Lee SW, Sawhney JPS, Kim HS, Krittayaphong R, Pocock SJ, Nhan VT, Alonso Garcia A, Chin CT, Jiang J, Jan S, Vega AM, Hayashi N, Ong TK. Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study. Clin Cardiol 2020;43:999-1008. [PMID: 32618009 DOI: 10.1002/clc.23400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc 2017;6:e005580. [PMID: 28411246 DOI: 10.1161/JAHA.117.005580] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
21 Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart 2017;103:573-80. [PMID: 28249994 DOI: 10.1136/heartjnl-2016-309871] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
22 Wang W, Wang X, Zhang L, Zhang J, Man F, Pan Q, Guo L. Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. Front Endocrinol (Lausanne) 2021;12:713849. [PMID: 34394007 DOI: 10.3389/fendo.2021.713849] [Reference Citation Analysis]
23 Su J, Yu Q, Zhu H, Li X, Cui H, Du W, Ji L, Tong M, Zheng Y, Xu H, Zhang J, Zhu Y, Xia Y, Liu T, Yao Q, Yang J, Chen X, Yu J. The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS One 2017;12:e0174511. [PMID: 28358842 DOI: 10.1371/journal.pone.0174511] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
24 Costa F, Windecker S, Valgimigli M. Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. Drugs 2017;77:1733-54. [PMID: 28853033 DOI: 10.1007/s40265-017-0806-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
25 McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum.Eur Heart J. 2017;38:3488-3492. [PMID: 29020292 DOI: 10.1093/eurheartj/ehx531] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 24.5] [Reference Citation Analysis]
26 Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016;315:1735-49. [PMID: 27022822 DOI: 10.1001/jama.2016.3775] [Cited by in Crossref: 514] [Cited by in F6Publishing: 292] [Article Influence: 102.8] [Reference Citation Analysis]
27 Chan Pin Yin DRPP, Ten Berg JM. Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options. Neth Heart J 2021. [PMID: 34357557 DOI: 10.1007/s12471-021-01604-4] [Reference Citation Analysis]
28 Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, Stone GW, Kalra A, Bhatt DL. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation 2020;142:1425-36. [PMID: 32795096 DOI: 10.1161/CIRCULATIONAHA.120.046308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 27.0] [Reference Citation Analysis]
29 Howard CE, Nambi V, Jneid H, Khalid U. Extended Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long? J Am Heart Assoc 2019;8:e012639. [PMID: 31576769 DOI: 10.1161/JAHA.119.012639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
30 Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB Sr, Braunwald E, Kereiakes DJ; DAPT Study Investigators. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016;37:378-85. [PMID: 26586780 DOI: 10.1093/eurheartj/ehv614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
31 Mullen L, Meah MN, Elamin A, Aggarwal S, Shahzad A, Shaw M, Hasara J, Rashid M, Fisher M, Ali T, Patel B, Ding WY, Grainger R, Heseltine T, Kirmani BH, Obeidat M, Kasolo Y, Thatchil J, Khand A. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice. J Am Heart Assoc 2021;10:e019467. [PMID: 33834845 DOI: 10.1161/JAHA.120.019467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Gajulapalli RD, Dias S, Pattanshetty DJ, Athappan G. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis. Anatol J Cardiol 2017;18:251-60. [PMID: 29076813 DOI: 10.14744/AnatolJCardiol.2017.7672] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Miyazaki Y, Suwannasom P, Sotomi Y, Abdelghani M, Tummala K, Katagiri Y, Asano T, Tenekecioglu E, Zeng Y, Cavalcante R, Collet C, Onuma Y, Serruys PW. Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol 2017;14:294-303. [PMID: 28181585 DOI: 10.1038/nrcardio.2017.12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
34 Lüscher TF. The management of acute coronary syndromes: towards optimal treatment of STEMI and non-STEMI. Eur Heart J 2016;37:203-5. [DOI: 10.1093/eurheartj/ehv747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Sharma A, Hai O, Garg A, Vallakati A, Lavie CJ, Marmur JD. Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Current Problems in Cardiology 2017;42:404-17. [DOI: 10.1016/j.cpcardiol.2017.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Bagai A, Wang TY, Goodman SG, Fisher HN, Welsh RC, Dery JP, Zhang X, Zhu YE, Cheema AN, Dehghani P, Kassam SA, Ducas J, Brass N, Kim HH, Fung A, Schampaert E, Quraishi AU, Mehta SR; Canadian Observational AntiPlatelet sTudy (COAPT) Investigators. Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. Int J Cardiol 2017;228:459-64. [PMID: 27870977 DOI: 10.1016/j.ijcard.2016.11.240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
37 Kikkert WJ, Damman P. Optimal duration of dual antiplatelet therapy for coronary artery disease. Neth Heart J 2018;26:321-33. [PMID: 29713989 DOI: 10.1007/s12471-018-1113-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Timmis A, Rapsomaniki E, Chung SC, Pujades-Rodriguez M, Moayyeri A, Stogiannis D, Shah AD, Pasea L, Denaxas S, Emmas C, Hemingway H. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations. BMJ 2016;353:i3163. [PMID: 27334486 DOI: 10.1136/bmj.i3163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
39 Rozemeijer R, Voskuil M, Greving JP, Bots ML, Doevendans PA, Stella PR. Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a meta-analysis of randomised trials. Neth Heart J 2018;26:242-51. [PMID: 29541996 DOI: 10.1007/s12471-018-1104-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Alomari M, Bratton H, Musmar A, Al Momani LA, Young M. Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention. Cureus 2019;11:e3874. [PMID: 30899625 DOI: 10.7759/cureus.3874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Savarese G, Savonitto S, Lund LH, Paolillo S, Marciano C, Dellegrottaglie S, Parente A, Trimarco B, Luscher TF, Perrone-filardi P. Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. Eur Heart J Cardiovasc Pharmacother 2016;2:218-28. [DOI: 10.1093/ehjcvp/pvw011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
43 Schoener L, Jellinghaus S, Richter B, Pfluecke C, Ende G, Christoph M, Quick S, Loehn T, Speiser U, Poitz DM, Mierke J, Strasser RH, Ibrahim K. Reversal of the platelet inhibitory effect of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new approach to an old issue. Clin Res Cardiol 2017;106:868-74. [PMID: 28653184 DOI: 10.1007/s00392-017-1128-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
44 Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimský P, Avezum A, Diaz R, Lewis BS, Berkowitz SD, Fox KAA, Ryden L, Yusuf S; COMPASS Steering Committee and Investigators. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation 2020;141:1841-54. [PMID: 32223318 DOI: 10.1161/CIRCULATIONAHA.120.046448] [Cited by in Crossref: 45] [Cited by in F6Publishing: 10] [Article Influence: 45.0] [Reference Citation Analysis]
45 Tangri N, Ferguson TW, Whitlock RH, Rigatto C, Jassal DS, Kass M, Toleva O, Komenda P. Long term health outcomes in patients with a history of myocardial infarction: A population based cohort study. PLoS One 2017;12:e0180010. [PMID: 28700669 DOI: 10.1371/journal.pone.0180010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
46 Chen YT, Chen HT, Hsu CY, Chao PW, Kuo SC, Ou SM, Shih CJ. Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis. Clin J Am Soc Nephrol 2017;12:262-71. [PMID: 28174317 DOI: 10.2215/CJN.04430416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
47 Gillette M, Morneau K, Hoang V, Virani S, Jneid H. Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. Curr Atheroscler Rep 2016;18:35. [PMID: 27139709 DOI: 10.1007/s11883-016-0581-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
48 Roffi M, Gencer B, Storey RF, Andreotti F, Patrono C. Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Curr Cardiol Rep 2016;18:48. [PMID: 27068306 DOI: 10.1007/s11886-016-0722-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB Sr, Massaro JM, van der Graaf Y, Cramer MJM, Kappelle LJ, de Borst GJ, Steg PG, Visseren FLJ. Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. J Am Heart Assoc 2018;7:e009217. [PMID: 30369323 DOI: 10.1161/JAHA.118.009217] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
50 Mok Y, Ballew SH, Bash LD, Bhatt DL, Boden WE, Bonaca MP, Carrero JJ, Coresh J, D'Agostino RB Sr, Elley CR, Fowkes FGR, Jee SH, Kovesdy CP, Mahaffey KW, Nadkarni G, Peterson ED, Sang Y, Matsushita K. International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. J Am Heart Assoc 2018;7:e008426. [PMID: 29982232 DOI: 10.1161/JAHA.117.008426] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
51 Montalescot G, Crea F. The year in cardiology 2015: acute coronary syndromes. Eur Heart J 2016;37:221-8. [DOI: 10.1093/eurheartj/ehv686] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
52 Berger JS. Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. Am J Cardiovasc Drugs 2018;18:457-72. [PMID: 29987548 DOI: 10.1007/s40256-018-0291-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
53 Wimmer NJ, Dufour AB, Cho K, Gagnon DR, Quach L, Ly S, Do JM, Ostrowski S, Michael Gaziano J, Faxon DP, Kinlay S. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting. Catheter Cardiovasc Interv 2017;89:1176-84. [PMID: 27860195 DOI: 10.1002/ccd.26831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
54 Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol 2019;14:810-22. [PMID: 31010936 DOI: 10.2215/CJN.12901018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
55 Dind A, Allahwala U, Asrress KN, Jolly SS, Bhindi R. Contemporary Management of ST-Elevation Myocardial Infarction. Heart Lung Circ 2017;26:114-21. [PMID: 27617370 DOI: 10.1016/j.hlc.2016.07.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
56 Su J, Zheng N, Li Z, Huangfu N, Mei L, Xu X, Zhang L, Chen X. Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients. J Clin Lab Anal 2020;34:e23040. [PMID: 31605429 DOI: 10.1002/jcla.23040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
57 Westermann D, Goodman SG, Nicolau JC, Requena G, Maguire A, Chen JY, Granger CB, Grieve R, Pocock SJ, Blankenberg S, Vega AM, Yasuda S, Simon T, Brieger D; TIGRIS Study Investigators. Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. Clin Cardiol 2017;40:1197-204. [PMID: 29247524 DOI: 10.1002/clc.22837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
58 Mazlan-Kepli W, Dawson J, Berry C, Walters M. Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome. Heart 2019;105:67-74. [PMID: 30030335 DOI: 10.1136/heartjnl-2018-313148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
59 Tan JW, Chew DP, Abdul Kader MAS, Ako J, Bahl VK, Chan M, Park KW, Chandra P, Hsieh IC, Huan DQ, Johar S, Juzar DA, Kim BK, Lee CW, Lee MK, Li YH, Almahmeed W, Sison EO, Tan D, Wang YC, Yeh SJ, Montalescot G. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region. Eur Cardiol 2021;16:e02. [PMID: 33708263 DOI: 10.15420/ecr.2020.40] [Reference Citation Analysis]
60 Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, di Uccio FS, Urbinati S, Varbella F, Zito GB, De Luca L; ESC Scientific Document Group ., Faculty for approval of the Consensus Document . Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. Eur Heart J Suppl 2018;20:F1-F74. [PMID: 29867293 DOI: 10.1093/eurheartj/suy019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
61 Lohaus R, Michel J, Mayer K, Lahmann AL, Byrne RA, Wolk A, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Wöhrle J, Kufner S, Morath T, Ibrahim T, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A, Schulz-Schüpke S. Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. Sci Rep 2016;6:33054. [PMID: 27624287 DOI: 10.1038/srep33054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
62 Halbach M, Baldus S. [Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]. Internist (Berl) 2018;59:288-303. [PMID: 29340741 DOI: 10.1007/s00108-017-0362-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Steg PG, Bhatt DL. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. European Heart Journal: Acute Cardiovascular Care 2016;6:93-7. [DOI: 10.1177/2048872615610868] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
64 Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017;38:1034-43. [PMID: 28110296 DOI: 10.1093/eurheartj/ehw627] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
65 Capodanno D, Alberts M, Angiolillo DJ. Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol 2016;13:609-22. [PMID: 27489191 DOI: 10.1038/nrcardio.2016.111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
66 Bundhun PK, Yanamala CM, Huang F. Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies. BMC Cardiovasc Disord 2016;16:161. [PMID: 27577530 DOI: 10.1186/s12872-016-0343-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]